Laboratorios Farmaceuticos ROVI (ROVI)

Currency in EUR
55.850
+0.100(+0.18%)
Real-time Data·

ROVI Financial Summary

Key Ratios

P/E Ratio21.6
Price/Book5.04
Debt / Equity22.5%
Return on Equity25.01%
Dividend Yield1.36%
EBITDA199.62M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of EUR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.59%
Dividend Yield
1.36%
Industry Median 2.77%
Annualised payout
0.76
Paid unevenly
5-Years Growth
+39.80%
Growth Streak

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 78.950
(+41.36% Upside)

Earnings

Latest Release
Jul 24, 2025
EPS / Forecast
0.42 / --
Revenue / Forecast
160.00M / 161.30M
EPS Revisions
Last 90 days

FAQ

What were Laboratorios Farmaceuticos ROVI's earnings for the latest quarter?

The Laboratorios Farmaceuticos ROVI EPS (TTM) is 2.59. Laboratorios Farmaceuticos ROVI reported sales of 159.70, net income of 21.64, and EPS of 0.42 for the latest quarter.

What was Laboratorios Farmaceuticos ROVI's net income for the latest quarter?

Laboratorios Farmaceuticos ROVI's net income for the latest quarter was 21.64.

How did Laboratorios Farmaceuticos ROVI's performance compare year-over-year in the latest quarter?

The company's revenue moved from 154.89 in the previous quarter to 159.70 in the latest quarter, and net income moved from 18.10 to 21.64 compared to the previous quarter.

What is Laboratorios Farmaceuticos ROVI's net profit margin on a TTM basis?

Laboratorios Farmaceuticos ROVI's trailing twelve months (TTM) net profit margin is 17.92%.

How does Laboratorios Farmaceuticos ROVI's debt to equity ratio compare to industry standards?

Laboratorios Farmaceuticos ROVI's total debt-to-equity ratio is 22.50%.

What is Laboratorios Farmaceuticos ROVI's return on investment on a TTM basis?

Laboratorios Farmaceuticos ROVI's trailing twelve months (TTM) return on investment (ROI) is 25.01%.

Did Laboratorios Farmaceuticos ROVI gain or lose cash last quarter?

In the latest quarter, Laboratorios Farmaceuticos ROVI's net change in cash was 16.81 million.

What were Laboratorios Farmaceuticos ROVI's total assets and liabilities in the latest quarter?

As of the latest quarter, Laboratorios Farmaceuticos ROVI reported total assets of 869.61 million and total liabilities of 186.51 million.

How has Laboratorios Farmaceuticos ROVI's total revenue grown this year?

Laboratorios Farmaceuticos ROVI's total revenue was 154.89 in the previous quarter and 159.70 in the latest quarter.

What is Laboratorios Farmaceuticos ROVI's gross margin on a TTM basis?

Laboratorios Farmaceuticos ROVI's trailing twelve months (TTM) gross margin is 62.40%.

What was Laboratorios Farmaceuticos ROVI's revenue per share for the latest quarter?

Laboratorios Farmaceuticos ROVI's revenue per share for the latest quarter was 9.85.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.